DoseGear research brief
Investigational dual receptor agonist targeting metabolic disease through balanced GLP-1R and GCGR activation. Phase 2/3 clinical trials demonstrate superior weight loss and MASH treatment efficacy.
DG Peptide Protocols
Extensively StudiedWeight LossMetabolic
Survodutide
BI 456906
Dual GLP-1/Glucagon Receptor Agonist | Weight Loss & Diabetes
Research overview
Mechanism of action
Dual agonism: GLP-1R reduces appetite and slows gastric emptying; GCGR increases energy expenditure and hepatic fat oxidation. EC50 0. 52nM GCGR, 0. 33nM GLP-1R.
Compound background
Development & research timeline
Study windows describe what researchers measured, not when an individual should expect a result.
Origin & development
Engineered dual GLP-1/glucagon-receptor agonist.
What it is researched for
Obesity, diabetes, and MASH research through combined GLP-1 and glucagon-receptor activation.
Research observation window
The source cites 16-week diabetes, 46-week obesity, and 48-week MASH trials.
Reference data
Lyophilized vial injectable protocols
Not personalized dosing instructions
Only injectable vial references are shown. Nasal, topical, and unsupported non-vial schedules are excluded.
| Research context | Amount | Frequency | Route |
|---|---|---|---|
| Obesity - Conservative Start | 0.6mg titrated over 24 weeks | Once weekly with 4-week intervals | SubQ |
| Obesity - Standard Protocol | 3.6-6.0mg | Once weekly | SubQ |
| MASH Treatment | 2.4-4.8mg | Once weekly | SubQ |
| Type 2 Diabetes | 0.3-2.7mg | Once weekly | SubQ |
Reference cycle
24-76+ weeks continuous therapy
Reference storage
Reconstituted: 2-8°C immediately after mixing
Safety context
Reported side effects
- Nausea (40-66%)
- Diarrhea (25-49%)
- Vomiting (15-41%)
- Slight heart rate increase (mean 2-5 bpm)
Contraindications & cautions
- Not recommended in pregnancy or breastfeeding
- Use contraception during treatment
Scientific references
- 01
Phase 2 Obesity Trial Without Diabetes
Scientific citationPhase 2 Obesity Trial Without Diabetes. (2024). - 02
Phase 2 MASH and Fibrosis Trial
Scientific citationPhase 2 MASH and Fibrosis Trial. (2024). - 03
Phase 2 Type 2 Diabetes Trial
Scientific citationPhase 2 Type 2 Diabetes Trial. (2023).
This DoseGear profile combines published scientific literature with lyophilized-vial protocol references. Citations are provided for independent review.